irinotecan has been researched along with cyclin d1 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, JF; Kargman, S; Kelly, CR; Kwong, E; Lam, EC; Luk, P; Wolfe, MM; Yao, M; Zheng, Y | 1 |
| Laurent-Puig, P; Lièvre, A | 1 |
| Ducreux, M; Laurent-Puig, P; Lièvre, A; Loriot, MA | 1 |
| Antonelli, A; Berti, P; Bocci, G; Canu, B; Cosconati, S; Da Settimo, F; Danesi, R; Di Desidero, T; Fioravanti, A; Frati, R; La Motta, C; Miccoli, P; Mugnaini, L; Orlandi, P; Sartini, S | 1 |
| Fujibuchi, W; Miura, K; Unno, M | 1 |
| Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS | 1 |
| Barszcz, K; Bernas, T; Czarnecka, J; Kaminska, B; Kominek, A; Piwocka, K; Was, H | 1 |
| Kitanaka, S; Miyata, S; Nakamura, T | 1 |
2 review(s) available for irinotecan and cyclin d1
| Article | Year |
|---|---|
[Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Colorectal Neoplasms; Cyclin D1; Drug Eruptions; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gene Dosage; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Irinotecan; Mutation; Neoplasm Proteins; Panitumumab; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Vascular Endothelial Growth Factor A | 2008 |
Splice isoforms as therapeutic targets for colorectal cancer.
Topics: Alternative Splicing; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Glucuronosyltransferase; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Pregnane X Receptor; Protein Isoforms; Receptors, Steroid; Survivin; Vascular Endothelial Growth Factor A | 2012 |
6 other study(ies) available for irinotecan and cyclin d1
| Article | Year |
|---|---|
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Camptothecin; Cell Division; Colorectal Neoplasms; Cyclin D1; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoskeletal Proteins; Dinoprostone; Drug Synergism; Endothelial Growth Factors; Fluorouracil; Intercellular Signaling Peptides and Proteins; Interleukin-10; Interleukin-12; Irinotecan; Isoenzymes; Lactones; Liver Neoplasms, Experimental; Lymphokines; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Prostaglandin-Endoperoxide Synthases; Sulfones; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (NADP); Epidermal Growth Factor; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptors, IgG; Thymidylate Synthase | 2008 |
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin D1; Drug Therapy, Combination; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2011 |
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors | 2014 |
Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.
Topics: Antineoplastic Agents; Cellular Senescence; Colonic Neoplasms; Cyclin D1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; HCT116 Cells; Humans; Hyaluronan Receptors; Irinotecan; Neoplastic Stem Cells; Oxaliplatin | 2018 |
3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Diterpenes; Drug Resistance, Neoplasm; Enzyme Activation; Glycogen Synthase Kinase 3 beta; Histones; Humans; Irinotecan; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Tumor Suppressor Protein p53 | 2020 |